PHLQX Holdings — PGIM Jennison Health Sciences Fund
All 55 reported holdings of PGIM Jennison Health Sciences Fund (PHLQX) by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets | Value (USD) |
|---|---|---|
| Eli Lilly & Company | 17.35% | $240.89M |
| Merck & Company, Inc. | 6.06% | $84.16M |
| Unitedhealth Group, Inc. | 5.87% | $81.45M |
| Thermo Fisher Scientific, Inc. | 4.56% | $63.27M |
| Argenx SE | 3.55% | $49.35M |
| Vertex Pharmaceuticals, Inc. | 3.37% | $46.73M |
| Danaher Corp. | 3.28% | $45.58M |
| Intuitive Surgical, Inc. | 3.07% | $42.69M |
| Lonza Group AG | 3.02% | $41.95M |
| Cvs Health Corp. | 2.52% | $35.00M |
| (PIPA070) PGIM Core Government Money Market Fund | 2.50% | $34.66M |
| Insmed, Inc. | 2.28% | $31.66M |
| Roivant Sciences Ltd. | 2.21% | $30.66M |
| Stryker Corp. | 2.16% | $29.95M |
| Sionna Therapeutics, Inc. | 2.01% | $27.88M |
| Beone Medicines Ltd. | 1.82% | $25.24M |
| Vaxcyte, Inc. | 1.77% | $24.65M |
| Align Technology, Inc. | 1.75% | $24.31M |
| Agilent Technologies, Inc. | 1.73% | $23.99M |
| Palvella Therapeutics, Inc. | 1.56% | $21.68M |
| Apogee Therapeutics, Inc. | 1.42% | $19.75M |
| Cabaletta Bio, Inc. | 1.35% | $18.75M |
| Prudential Investment Portfolios 9 | 1.31% | $18.20M |
| Newamsterdam Pharma Company NV | 1.30% | $17.99M |
| Dianthus Therapeutics, Inc. | 1.28% | $17.74M |
| Kymera Therapeutics, Inc. | 1.26% | $17.56M |
| Scholar Rock Holding Corp. | 1.25% | $17.36M |
| Celcuity, Inc. | 1.07% | $14.81M |
| Revolution Medicines, Inc. | 1.06% | $14.78M |
| Astrazeneca PLC | 1.06% | $14.68M |
| Mineralys Therapeutics, Inc. | 1.04% | $14.48M |
| Teva Pharmaceutical Industries Ltd. | 1.00% | $13.93M |
| Xenon Pharmaceuticals, Inc. | 1.00% | $13.84M |
| Disc Medicine, Inc. | 0.99% | $13.78M |
| Protagonist Therapeutics, Inc. | 0.97% | $13.47M |
| Bayer AG | 0.94% | $13.02M |
| Veradermics, Inc. | 0.93% | $12.88M |
| Tandem Diabetes Care, Inc. | 0.84% | $11.70M |
| Erasca, Inc. | 0.81% | $11.27M |
| Crinetics Pharmaceuticals, Inc. | 0.71% | $9.86M |
| Tarsus Pharmaceuticals, Inc. | 0.70% | $9.66M |
| Immunovant, Inc. | 0.67% | $9.25M |
| Avalyn Pharma, Inc. | 0.66% | $9.17M |
| Olema Pharmaceuticals, Inc. | 0.63% | $8.74M |
| Elanco Animal Health, Inc. | 0.62% | $8.56M |
| Arcutis Biotherapeutics, Inc. | 0.60% | $8.40M |
| Seaport Therapeutics, Inc. | 0.57% | $7.98M |
| Abivax SA | 0.54% | $7.50M |
| Uniqure NV | 0.51% | $7.14M |
| Lb Pharmaceuticals, Inc. | 0.47% | $6.47M |
| Tyra Biosciences, Inc. | 0.44% | $6.11M |
| Enliven Therapeutics, Inc. | 0.36% | $4.97M |
| Spyre Therapeutics, Inc. | 0.34% | $4.71M |
| Oruka Therapeutics, Inc. | 0.32% | $4.47M |
| Cabaletta Bio, Inc. Warrant | 0.20% | $2.74M |
PHLQX overview: performance, fees, allocation and SEC filings